Aims and Scope

ReviewerCreditsCurrent Cancer Reports (CCR) (eISSN: 2661-3166) is an open access, continuously published, international, refereed journal dedicated to publish articles covering all areas of carcinogenesis, prevention, diagnosis, treatment, drug development and related policy.

The journal aims at promoting research communications, and providing a platform for doctors, researchers, physicians, pharmacists and healthcare professionals to find the most recent advances in all areas of cancer-related fields. Current Cancer Reports accepts original research articles, reviews, minireviews, case reports, image data, novel hypothesis and rapid communication covering all respects of carcinogenesis and cancer therapy.

The columns of the journal include, but not limited to:
• Original articles and new techniques in cancer research and therapy
• Quick reports
• Case reports
• Clinicopathologic discussion
• Discussion of clinical case
• Expert views
• Exchange of experience
• Novel hypothesis
• Correspondence
• Publish the original incoming letter
• Academic contending/Debate
• etc.

Vol 6 (2024)

Published: 2024-07-02

Abstract views: 487   PDF downloads: 66  
2024-08-27

Page 205-224

Deep learning based capsule networks for breast cancer classification using ultrasound images

blankpage Stephen Afrifa, Vijayakumar Varadarajan, Tao Zhang, Peter Appiahene, Daniel Gyamfi, Rose-Mary Owusuaa Mensah Gyening, Jacob Mensah, Samuel Opoku Berchie

Purposes: Breast cancer (BC) is a disease in which the breast cells multiply uncontrolled. Breast cancer is one of the most often diagnosed malignancies in women worldwide. Early identification of breast cancer is critical for limiting the impact on affected people's health conditions. The influence of technology and artificial intelligence approaches (AI) in the health industry is tremendous as technology advances. Deep learning (DL) techniques are used in this study to classify breast lumps.
Materials and Methods: The study makes use of two distinct breast ultrasound images (BUSI) with binary and multiclass classification. To assist the models in understanding the data, the datasets are exposed to numerous preprocessing and hyperparameter approaches. With data imbalance being a key difficulty in health analysis, due to the likelihood of not having a condition exceeding that of having the disease, this study applies a cutoff stage to impact the decision threshold in the datasets data augmentation procedures. The capsule neural network (CapsNet), Gabor capsule network (GCN), and convolutional neural network (CNN) are the DL models used to train the various datasets.
Results: The findings showed that the CapsNet earned the maximum accuracy value of 93.62% while training the multiclass data, while the GCN achieved the highest model accuracy of 97.08% when training the binary data. The models were also evaluated using a variety of performance assessment parameters, which yielded consistent results across all datasets.
Conclusion: The study provides a non-invasive approach to detect breast cancer; and enables stakeholders, medical practitioners, and health research enthusiasts a fresh view into the analysis of breast cancer detection with DL techniques to make educated judgements.

Abstract views: 421   PDF downloads: 92  
2024-07-02

Page 193-204

Nanotherapeutics to cure inflammation-induced cancer

blankpage Rajiv Kumar

Aims: Nanotherapeutics are being explored as a potential solution to treat inflammation-induced cancer. Nanotherapeutics enhance innate immune cells' immunity, enabling them to fight tumors effectively. These cells secrete specific chemicals like cytokines, allowing them to replicate quickly and respond to future threats, making them suitable for immunotherapy.
Methods: Nanotechnology can significantly improve human health by enhancing infection detection, prevention, and treatment. Nanomedicines, composed of restorative and imaging compounds in submicrometer-sized materials, aim to deliver effective treatments and limit inflammation in healthy body areas. Combining nanotechnology and clinical sciences, nanoparticles are suitable for gene therapy and have been developed for treating various diseases, including cancer, cardiovascular, diabetes, pulmonary, and inflammatory diseases.
Results: Neutrophils and their offspring, including films and extracellular vehicles, are crucial drug transporters for enhanced growth therapy. Tumor microenvironment inputs can modify tumor-associated neutrophils (TANs), which are essential for tumor growth and healing. Human tumor intratumor heterogeneity is crucial for tumor growth and healing. Nanomedicines have shown potential in targeted delivery, toxicity reduction, and therapeutic effectiveness enhancement. However, clinical relevance and efficacy remain inadequate due to a lack of understanding of the interaction between nanomaterials, nanomedicine, and biology. The diverse biological milieu impacts the dynamic bioidentity of nanoformulations, and their interactions can modify therapeutic function or cellular absorption.
Conclusion: Nanotechnology holds great promise for improving human health by detecting, preventing, and treating infections. Nanomedicines, a fusion of clinical sciences and nanotechnology, use submicrometer-sized transporter materials for therapy delivery and reducing contamination. Nanoparticles' small size and high surface-to-volume ratio can benefit gene therapy. Research has led to a wide range of nanomedicine products globally.

Abstract views: 143   PDF downloads: 39  
2024-09-11

Page 225-229

Opportunities and challenges of multidisciplinary conversion therapy in advanced hepatocellular carcinoma

blankpage Ju-Hang Chu, Lu-Yao Huang, Ya-Ru Wang, Jun Li, Ying-Yu Cui, Ming-Ping Qian

Surgical resection is still the most important radical treatment for primary hepatocellular carcinoma (HCC), but at present, the resection rate of newly diagnosed patients with HCC is only 30%. The recurrence rate of newly diagnosed patients suitable for surgical resection within 5 years after surgery is as high as 40%~70%. Low initial resection rate and high postoperative recurrence rate are important reasons restricting the overall treatment effects of HCC in China. Under this background, effectively improving the resection rate of HCC and reducing the postoperative recurrence rate have become the key topics to improve the treatment effects of HCC. Some initially unresectable HCC patients may have access to surgery through conversion therapy. Conversion therapy, which mainly involves the combination of local, systemic, and multiple treatment strategies, offers hope for patients with advanced HCC. But there are still some patients who do not benefit from conversion therapy. So, how to improve the conversion success rate is still one of the challenges that clinicians need to solve.

View All Issues
Yuesuo Yang-photo  eISSN: 2661-3166
 Abbreviation: Curr Cancer Rep
 Editor-in-Chief: Prof. Yingyu Cui
 Publishing Frequency: Continuous publication
 Article Processing Charges (APC):
Click  here  for more details
 Publishing Model:
Open Access